Medical Policy

Title: Intra-Articular Hyaluronan Injections for Osteoarthritis

State and Federal mandates and health plan member contract language, including specific provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. To verify a member’s benefits, contact Blue Cross and Blue Shield of Kansas Customer Service.

The BCBSKS Medical Policies contained herein are for informational purposes and apply only to members who have health insurance through BCBSKS or who are covered by a self-insured group plan administered by BCBSKS. Medical Policy for FEP members is subject to FEP medical policy which may differ from BCBSKS Medical Policy.

The medical policies do not constitute medical advice or medical care. Treating health care providers are independent contractors and are neither employees nor agents of Blue Cross and Blue Shield of Kansas and are solely responsible for diagnosis, treatment and medical advice.

If your patient is covered under a different Blue Cross and Blue Shield plan, please refer to the Medical Policies of that plan.

<table>
<thead>
<tr>
<th>Populations</th>
<th>Interventions</th>
<th>Comparators</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Individuals: • With osteoarthritis of the knee</td>
<td>Interventions of interest are: • Intra-articular hyaluronan injections</td>
<td>Comparators of interest are: • Physical therapy • Medication • Surgery</td>
<td>Relevant outcomes include: • Symptoms • Functional outcomes • Treatment-related morbidity</td>
</tr>
<tr>
<td>Individuals: • With osteoarthritis of joints other than the knee</td>
<td>Interventions of interest are: • Intra-articular hyaluronan injections</td>
<td>Comparators of interest are: • Physical therapy • Medication • Surgery</td>
<td>Relevant outcomes include: • Symptoms • Functional outcomes • Treatment-related morbidity</td>
</tr>
</tbody>
</table>
DESCRIPTION
Intra-articular (IA) injection of hyaluronan into osteoarthritic joints is proposed to improve pain and function. It is thought to replace endogenous hyaluronan, restore the viscoelastic properties of the synovial fluid. Most studies to date have assessed hyaluronan injections for knee osteoarthritis, and this is the U.S. Food and Drug Administration-approved indication. Other joints, such as the hip and shoulder, are being investigated for IA hyaluronan treatment of osteoarthritis.

OBJECTIVE
The objective of this policy is to evaluate whether intra-articular injection of hyaluronan improves health outcomes in patients with osteoarthritis of the knee and other joints (e.g., hip, shoulder).

BACKGROUND
Knee osteoarthritis (OA) is common, costly, and a cause of substantial disability. Among U.S. adults, the most common causes of disability are arthritis and rheumatic disorders. Currently, no curative therapy is available for OA, and thus the overall goals of management are to reduce pain, disability, and the need for surgery.

Intra-articular injection of hyaluronan has been proposed as a means of restoring the normal viscoelasticity of the synovial fluid in patients with OA and improving pain and function. This treatment may also be called viscosupplementation. Hyaluronan is a naturally occurring macromolecule that is a major component of synovial fluid and is thought to contribute to its viscoelastic properties. Chemical crosslinking of hyaluronan increases its molecular weight; cross-linked hyaluronans are referred to as hylans. In OA, the overall length of hyaluronan chains present in cartilage and the hyaluronan concentration in the synovial fluid are decreased.

REGULATORY STATUS
Several preparations of intra-articular (IA) hyaluronan have been approved by the U.S. Food and Drug Administration (FDA) as an alternative to nonsteroidal anti-inflammatory drug therapy in the treatment of osteoarthritis (OA) of the knee: Synvisc® and Synvisc-One® (Genzyme); Gel-One® (Zimmer); Hyalgan® (Fidia); Supartz FX™ (Bioventus); Orthovisc® (Anika); Euflexxa®, previously named Nuflexxa (Savient); Monovisc® (Anika Therapeutics); and Gel-Syn™ (Institut Biochimique SA). All products are manufactured from rooster combs except for Euflexxa, Orthovisc, Monovisc, Gel-Syn, and GenVisc 850, which are produced from bacterial fermentation. Also, Synvisc undergoes additional chemical crosslinking to create hylans with increased molecular weight (6000 kDa) compared with Hyalgan (500-730 kDa) and Supartz (620-1170 kDa). Monovisc is also cross-linked with a proprietary cross-linker. The differing molecular weights of the products lead to different half-lives; the half-life of Hyalgan or Supartz is estimated at 24 hours, while the half-life of Synvisc may range up to several days.

According to the manufacturer’s prescribing information for Synvisc and Euflexxa, IA hyaluronan is “indicated for the treatment of pain in osteoarthritis of the knee in patients..."
who have failed to respond adequately to conservative nonpharmacologic therapy, and to simple analgesics, eg, acetaminophen.” The product inserts further indicate that Synvisc and Euflexxa should be injected intra-articularly into the knee joint once per week for a total of 3 injections over a 2- to 3-week period. In contrast, 5 weekly injections are recommended for the Hyalgan and Supartz products, and 3 to 4 weekly injections are recommended for Orthovisc. In February 2009, FDA approved the use of single-dose hylan G-F 20 (Synvisc-One) for the treatment of OA of the knee. In 2011, FDA approved the use of the single-dose cross-linked hyaluronate Gel-One (also known as Gel-200) for the treatment of OA of the knee. In 2014, Monovisc was also approved as a single-dose treatment, while Gel-Syn was approved as a course of 3 weekly injections. In 2015, GenVisc 850 was approved as a course of 3 weekly injections.

In 2000, FDA approved removal of a precautionary statement from the package inserts for Hyalgan® and Synvisc® that stated that the safety and efficacy of repeat courses have not been established.

FDA has not approved intra-articular hyaluronan for joints other than the knee.

FDA product code: MOZ.
POLICY
A. Intra-articular hyaluronan injections of the knee are considered not medically necessary.

B. Intra-articular hyaluronan injections are considered experimental / investigational for all other joints.

RATIONALE
This evidence review has been updated regularly with searches of the MEDLINE database. The most recent literature review was performed through February 23, 2017.

Assessment of efficacy for a therapeutic intervention involves a determination of whether the technology improves health outcomes. The optimal study design for this purpose is a randomized controlled trial (RCT) that includes clinically relevant measures of health outcomes. Intermediate outcome measures, also known as surrogate outcome measures, may also be adequate if there is an established link between the intermediate outcome and true health outcomes. Nonrandomized comparative studies and uncontrolled studies can sometimes provide useful information on health outcomes, but are prone to biases such as noncomparability of treatment groups, the placebo effect, and variable natural history of the condition. As there are a number of RCTs on intra-articular (IA) hyaluronan for osteoarthritis (OA), this evidence review will focus on RCTs and systematic reviews.

Knee Osteoarthritis
This evidence review was originally based on a 1998 TEC Assessment on IA hyaluronan injections for OA, and incorporated material from subsequent TEC Assessments and a TEC review for Agency for Healthcare Research and Quality (AHRQ). The 2007 AHRQ report concluded that results from 42 generally showed positive effects of viscosupplementation on pain and function scores compared with placebo for patients with primary OA of the knee. However, the evidence on viscosupplementation was accompanied by considerable uncertainty due to variable trial quality, potential publication bias, and unclear clinical significance of the changes reported. A 2016 protocol for an update of the 2007 AHRQ report does not support IA hyaluronan because the technical expert panel concluded the evidence did not need updating.

The 2014 TEC Assessment involved a systematic review of recent meta-analyses on the treatment of knee OA with IA hyaluronan injections. Included in the assessment were 5 meta-analyses published between 2011 and 2013. Two meta-analyses concluded that IA hyaluronan provides a clinically meaningful benefit and 3 concluded that it did not, due to a lack of supportive evidence. It was not possible from the data to determine the proportions of patients achieving clinically meaningful improvement, although the analysis from the American Academy of Orthopaedic Surgeons determined that it was unlikely that an appreciable number of patients would benefit compared with placebo. It is also possible that the results supporting a clinically meaningful benefit were biased in favor of IA hyaluronan, due to unpublished trial data. When results from unpublished trials were obtained, the magnitude of treatment effect was notably lower compared with published results. Substantial heterogeneity between trials was also evident, increasing uncertainty. The TEC Assessment concluded that the 5 meta-analyses, sampling from a similar collection of published trials and 2 unpublished ones, highlight biases and difficulty ascertaining clinically meaningful patient-level improvement compared with placebo. Although accumulating evidence would be expected to increase certainty about whether a
clinically important treatment benefit exists, the current studies do not provide convincing evidence that the net health outcome is improved with IA hyaluronan over placebo.

Literature reviews in 2016 and 2017 identified a number of additional systematic reviews and meta-analyses, published after the 2014 TEC Assessment. Some of these systematic reviews reported pooled analyses synthesizing results of RCTs that compared IA hyaluronan with placebo, and reported the outcome, pain. Three of the new meta-analyses concluded that IA hyaluronan injections for knee OA provided a clinically meaningful reduction in pain compared with placebo. One meta-analysis (Jevsevar et al [2015]) concluded that evidence from trials at low risk of bias (e.g., double-blind, sham-controlled) did not demonstrate a clinically meaningful benefit of IA hyaluronan. (Two of the meta-analyses concluding benefit of IA hyaluronan also limited analysis to trials at low risk of bias.) Two additional meta-analyses concluded that there was a small, statistically significant benefit and clinical significance depends on the threshold used. As noted in the 2014 TEC Assessment, “...for a standardized mean difference (SMD), a minimally important difference of -0.37 is sometimes cited...” The O’Hanlon (2016) meta-analysis of placebo-controlled, blinded trials found an SMD of -0.23. In contrast, the Johansen et al (2016) meta-analysis of placebo-controlled trials found an SMD of -0.39. However, when trials were stratified by risk of bias, the effect size of low-risk-of-bias trials was 0.0 and the effect sizes of the unclear and high-risk-of-bias trials were -0.81 and -0.35, respectively. Moreover, a stratified analysis by trial size found an SMD of -0.72, whereas trials with at least 100 patients showed an SMD of -0.21.

Conclusions that can be drawn from the newer meta-analyses are limited by potential biases with included trials. The presence of publication bias has been documented in the IA hyaluronan literature. Likewise, a small trial bias has been noted with effect estimates from smaller trials (<100 participants) almost 3-fold that of large trials. These observations are consistent with positive results from a small trial having a higher probability of being reported than a small negative one (or possibly a small negative trial having even been completed). In fact, the O’Hanlon (2016) meta-analysis did identify a small trial bias; although there was an overall positive impact of IA hyaluronan on pain, the effect size of small trials was much higher than that of large trials, and these effect sizes of large trials was below the level generally considered clinically significant. The results from the 2015-2016 meta-analyses (which did not include any new placebo-controlled randomized trials) do not alter conclusions of the 2014 TEC Assessment on the impact of IA hyaluronan on health outcomes in patients with knee OA.

No placebo-controlled RCTs published after the 2014 TEC Assessment were identified. However, two 2016 RCTs compared IA hyaluronan to corticosteroid injection. Neither found a clinically meaningful benefit of IA hyaluronan compared with corticosteroids. Limitations of both trials included lack of a placebo control group, making conclusions about the efficacy of IA hyaluronan compared with corticosteroids or placebo difficult to draw. Tammachote et al (2016) reported on a double-blind RCT in 110 patients with knee OA. Patients received 1 injection of IA hyaluronan or corticosteroid and were followed for 6 months. The primary outcome, pain at 6 months (measured by a 100-point visual analog scale [VAS]), did not differ significantly between groups. Mean VAS score at 6 months was 24 in the IA hyaluronan group and 21 in the corticosteroid group (p>0.05). At 1 week postinjection, reported pain levels were significantly lower in the corticosteroid group (mean VAS score, 14) than in the IA hyaluronan group (mean VAS score, 23; p=0.018).
The other RCT comparing IA hyaluronan to corticosteroid injection in patients with knee OA was published by Askari et al in 2016.22 Like the Tammachote (2016) study, it, too, was double-blind and involved a single injection. Patients were followed for 3 months, and pain was assessed using a 0- to 10-cm VAS. At follow-up, there were no significant differences in pain scores between the groups. Mean VAS score at 3 months was 6.70 in the IA hyaluronan group and 6.26 in the corticosteroid group (p=0.720). After 1 month, mean pain score was significantly lower in the corticosteroid group (mean VAS score, 5.59) than the IA hyaluronan group (mean VAS score, 6.63; p=0.018).

Section Summary: Knee Osteoarthritis
Many RCTs have been published over the last 2 decades. While the outcomes of these RCTs have been mixed, the RCT evidence base is characterized by studies showing small treatment effects of IA hyaluronan treatment. In many cases, these trials are at risk of bias, and it cannot be determined with certainty whether there is a true treatment effect or whether the reported differences are due to bias. Meta-analyses of RCTs have also had mixed findings. Some meta-analyses estimating the magnitude of treatment benefit have concluded that there is no clinically significant benefit; however, others have concluded that there is a clinically significant benefit. These meta-analyses have also highlighted the limitations of this evidence base, most notably publication bias and small trial bias. For example, a 2016 meta-analysis found more than a 3-fold larger treatment effect in small trials than in larger trials (ie, >100 participants). Overall, given the lack of a definitive treatment benefit despite a large quantity of literature, and given the biases present in the available evidence, it is unlikely there is a clinically meaningful treatment benefit.

Osteoarthritis of Joints Other Than the Knee
Ankle Osteoarthritis
The evidence was examined from published RCTs and systematic reviews. A 2015 Cochrane review by Witteveen et al addressed IA hyaluronan and other conservative treatments for ankle OA.23 Reviewers identified 6 RCTs, 3 of which were double-blind and compared IA hyaluronan with placebo. The other trials were single-blind. Two of them compared IA hyaluronan to another treatment (exercise in 1 study, botulinum toxin in the other) and the sixth trial compared different doses of hyaluronan. Five of the 6 trials included patients with unilateral ankle pain. Sample sizes at randomization ranged from 17 to 75, and length of follow-up ranged from 3 to 12 months. The authors pooled findings only for 2 of the 3 studies comparing IA hyaluronan and placebo. Meta-analyses of efficacy outcomes (pain, function) did not find statistically significant benefit favoring IA hyaluronan over placebo, with the exception of the outcome Ankle Osteoarthritis Scale (AOS) total score at 6 months. For the AOS outcome, the pooled effect size was -12.53 (95% confidence interval [CI], -23.84 to -1.22) in favor of IA hyaluronan; however, the evidence for this analysis was rated as low due to the limitation in study design (ie, unclear risk of bias) and “...imprecision of result (low number of participants).” No serious adverse events were reported and no patient withdrew from the trial due to an adverse event.

A 2011 review of IA hyaluronan for ankle OA by Migliore et al considered RCTs and observational studies.24 They identified 3 small RCTs with a total of 75 patients, and 4 case series. In 2 of the RCTs, IA hyaluronan was compared with placebo injection and the third RCT compared IA hyaluronan with exercise therapy. Reviewers were unable to conduct a meta-analysis due to the limited number of studies and study heterogeneity.
Foot Osteoarthritis
There is a very limited amount of evidence on IA hyaluronan injections in the foot. Munteanu et al (2011) reported on an RCT of a single IA hyaluronan injection in 151 patients with first metatarsophalangeal joint OA. At the 1-, 3-, and 6-month follow-ups, there were no significant differences between the IA hyaluronan and placebo groups on the Foot Health Status Questionnaire.

Thumb Osteoarthritis
Two systematic reviews have evaluated IA hyaluronan and corticosteroid injections for treating thumb OA. The 2016 review by Kroon et al identified 3 studies comparing IA hyaluronan and placebo and 6 comparing IA hyaluronan and corticosteroids. Findings from the IA hyaluronan studies were not pooled. Unlike the Kroon review, the 2015 systematic review by Trellu et al included only RCTs and pooled study data. Six trials (total N=428 patients) were included in the meta-analyses; 169 patients were treated with HA, 147 with corticosteroids, and 74 with placebo. In pooled analyses of trials comparing IA hyaluronan and placebo (74 patients in each arm), there was no significant between-group difference in pain at week 12 (standardized response mean [SRM], -0.95; 95% CI, -3.87 to 1.97); however, functional capacity at week 12 was significantly better after IA hyaluronan than after placebo (SRM = -1.14; 95% CI, -1.69 to -0.60). When IA hyaluronan and corticosteroids were compared, there were no significant differences in pain, functional capacity, or pulp pinch force at 12 weeks. At 24 weeks, findings were mixed. There was no significant between IA hyaluronan and corticosteroids in functional capacity, IA hyaluronan was superior on pulp pinch force status (SRM = -1.66; 95% CI, -0.75 to -2.57), and corticosteroids were superior on pain (SRM=1.44; 95% CI, 0.14 to 2.74).

Hip Osteoarthritis
A 2015 systematic review by Lieberman et al included RCTs and observational studies (with a minimum of 10 patients) evaluating IA hyaluronan for treatment of pain associated with hip OA. Twenty-three studies were identified, 6 of which were RCTs. The studies evaluated 11 different formulations of IA hyaluronan. Durations of follow-up varied; 19 studies followed patients for 6 months or less, 3 studies had between 6 months and 1 year of follow-up, and 1 study followed patients for more than 1 year. The primary efficacy outcome was change from baseline in pain measured by a VAS. Reviewers did not report the number of points on the VAS, but presumably this differed across studies and the authors appeared to standardize results on a 10-point VAS. A pooled analysis of data from all studies found a statistically significantly lower pain score at follow-up compared to baseline. Mean change was -1.97 points on the VAS (95% CI, -2.83 to -1.12). In a pooled analysis of the 6 RCTs, there was a significantly greater decrease in pain with IA hyaluronan than with a control intervention (-0.27 points on a VAS; 95% CI, -0.43 to -0.11). Although statistically significant, a between-group difference of 0.27 points on a VAS may not be clinically meaningful.

In 2016, Piccirilli et al published a systematic review of RCTs evaluating IA hyaluronan for any type of hip disorder. They identified 25 RCTs; the trials addressed hip OA, hip rheumatoid arthritis, and femoroacetabular impingement. Reviewers provided a table of individual studies and noted that studies used different modalities and protocols; no attempt was made to synthesize findings quantitatively or qualitatively.

Shoulder Osteoarthritis
A 2014 systematic review by Colen et al identified RCTs, controlled observational studies, and case series evaluating IA hyaluronan for treatment of glenohumeral OA in adults. Eight studies
met the eligibility criteria; 2 were RCTs, 5 were prospective case series, and 1 was a retrospective case-control study. Due to heterogeneity across studies and the small number of controlled studies, reviewers did not pool study findings on the efficacy of IA hyaluronan compared with placebo or an alternative intervention for treating shoulder OA. The RCTs are described next.

Blaine et al (2008) was an industry-sponsored trial, 3-arm of 660 patients with persistent shoulder pain due to glenohumeral joint OA, rotator cuff tear, and/or adhesive capsulitis that compared 3 weekly injections to 5 weekly injections of sodium hyaluronate (Hyalgan) and to 5 weekly injections of saline. Approximately 60% of patients had OA, although most with OA also had rotator cuff disorders or capsulitis. Sixty-nine percent (n=456) of the patients had a follow-up visit at 26 weeks. There was no significant difference among groups in the primary outcome measure (shoulder pain with movement at 13 weeks). Analysis of predefined, stratified subgroups revealed no significant differences in reported pain at 13 weeks but a statistically significant decrease of 7.5 mm and 7.8 mm (on a 100-mm VAS) in reported pain in both treatment groups at 26 weeks compared with placebo among patients with OA. In those without OA, there were no significant improvements with either regimen. Of note, this appears to be an as-treated analysis of the OA subgroup data, and the difference may not be clinically meaningful.

In 2013, Kwon et al published findings from a multicenter, randomized, double-blind, placebo-controlled trial of IA hyaluronan in 300 patients with glenohumeral OA. Intention-to-treat analysis found similar improvements from baseline in 100-mm VAS for pain (19.88 mm for IA hyaluronan, 16.29 mm for sham treatment) and in the Outcome Measures in Rheumatoid Clinical Trials–Osteoarthritis Research Society International (OMERACT-OARSI) high responder rate (40.8% for IA hyaluronan, 34.9% for sham) at 26 weeks. In a subset of IA hyaluronan patients, there were statistically significant differences of 4.0 mm in VAS score and 8.37% on the OMERACT-OARSI. However, the clinical significance of these differences is uncertain.

Spine Osteoarthritis
The data are limited to small pilot studies and case series.

Section Summary: Osteoporosis in Joints Other Than the Knee
The evidence for use of IA hyaluronan in joints other than the knee includes RCTs and systematic reviews for treating the ankle, thumb, hip, and shoulder. Meta-analyses of RCTs either have not found statistically significant benefits of the procedure on health outcomes or have found benefits that were statistically, but likely not clinically, significant (eg, 0.27-point improvement on a 10-point VAS for studies on hip OA). There were fewer published studies on treating foot joints and spine OA.

SUMMARY OF EVIDENCE
For individuals who have osteoarthritis of the knee who receive intra-articular (IA) hyaluronan injections, the evidence includes randomized controlled trials (RCTs) and systematic reviews of RCTs. Relevant outcomes are symptoms, functional outcomes, and treatment-related morbidity. Many RCTs have been published over the last 2 decades. While outcomes of these RCTs have been mixed, the RCT evidence base is characterized by studies showing small treatment effects of IA hyaluronan injections. In many cases, these trials are at risk of bias, and it cannot be determined with certainty whether there is a true treatment effect or whether the reported differences are due to bias. Meta-analyses of RCTs have also had mixed findings. Some meta-analyses estimating the magnitude of treatment benefit have concluded that there is no clinically
significant benefit; however, others have concluded that there is a clinically significant benefit. These meta-analyses have also highlighted the limitations of this evidence base, most notably publication bias and small trial bias. For example, a 2016 meta-analysis found more than a 3-fold larger treatment effect in small trials than in larger trials (ie, >100 participants). Overall, given the lack of a definitive treatment benefit despite a large quantity of literature, and given the biases present in the available evidence, it is unlikely there is a treatment benefit that is clinically meaningful. Overall, given the lack of a definitive treatment benefit despite a large quantity of literature, and given the biases present in the available evidence, it is unlikely there is a treatment benefit that is clinically meaningful. The evidence is sufficient to determine qualitatively that the technology is unlikely to improve the net health outcome.

For individuals who have osteoarthritis of joints other than the knee who receive IA hyaluronan injections, the evidence includes RCTs, systematic reviews of RCTs, and observational studies. Relevant outcomes are symptoms, functional outcomes, and treatment-related morbidity. Meta-analyses of RCTs either have not found statistically significant benefits of the procedure on health outcomes or have found benefits that were statistically, but likely not clinically, significant (eg, 0.27-point improvement on a 10-point visual analog scale for hip osteoarthritis). The evidence is insufficient to determine the effects of the technology on health outcomes.

**CLINICAL INPUT FROM PHYSICIAN SPECIALTY SOCIETIES AND ACADEMIC MEDICAL CENTERS**

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

In response to requests, input was received from 5 academic medical centers (6 reviewers) and 3 physician specialty societies while this policy was under review in 2011. Most reviewers agreed that IA hyaluronan of the knee was medically necessary. In addition, those providing input supported an interval of 6 months for repeat injections. In response to a question about total number of treatment courses, there was no consensus.

**PRACTICE GUIDELINES AND POSITION STATEMENTS**

**American Medical Society for Sport Medicine**

The 2016 scientific statement from the American Medical Society for Sport Medicine (AMSSM) recommended IA hyaluronan for “appropriate” patients with knee osteoarthritis (OA) based on high-quality evidence.14 Patient selection criteria include individuals age 60 and older with Kellgren-Lawrence grade 2-3 OA. The society also “suggests” IA hyaluronan for patients under age 60 with knee OA based on moderate quality indirect evidence.

**American Academy of Orthopaedic Surgeons**

The 2013 guideline of the American Academy of Orthopaedic Surgeons (AAOS) on treatment of OA of the knee states that they cannot recommend using IA hyaluronan for patients with symptomatic knee OA. This is a strong recommendation, meaning that the quality of the supporting evidence is high. This recommendation was based on a meta-analysis of 3 high-strength and 11 moderate-strength studies that showed that the overall effect was less than 0.5 minimally important different units, indicating a low likelihood that an appreciable number of patients achieved clinically important benefits. AAOS states that practitioners should follow a strong recommendation unless a clear and compelling rationale for an alternative approach is
present. This replaces a 2008 guideline in which a recommendation could not be made for IA hyaluronan due to inconclusive evidence.

The 2009 (reaffirmed 2014) AAOS Clinical Practice Guideline on glenohumeral joint osteoarthritis\(^{32}\) includes a weak grade C recommendation that “The use of injectable viscosupplementation is an option when treating patients with glenohumeral [shoulder] osteoarthritis.” Grade C recommendations are based on poor-quality evidence. In this instance, the recommendation is based on a single case series of 30 patients with OA of the glenohumeral joint who received 3 weekly IA injections of Synvisc.\(^{34}\) At 1, 3, and 6 months, clinically significant improvements were seen in pain, function, and quality-of-life measures.

American College of Rheumatology
The American College of Rheumatology (ACR) published updated guidelines in 2012 that addressed OA of the hand, hip, and knee.\(^{35}\) A conditional recommendation was given for IA hyaluronan to treat OA of the knee. ACR recommends not using IA hyaluronan for OA of the hand. For OA of the hip, ACR explicitly made no recommendation regarding treatment with IA hyaluronan due to the lack of RCTs.

Osteoarthritis Research Society International
The 2014 Osteoarthritis Research Society International guidelines, developed by consensus after review of existing guidelines and systematic reviews, gave an “uncertain” recommendation for the use of IA hyaluronan for knee OA and a recommendation of “not appropriate” for multiple-joint OA.\(^{36}\)

National Institute for Health and Care Excellence
The 2014 guidelines by the National Institute for Health and Care Excellence\(^{37}\) state: “Do not offer intra-articular hyaluronan injections for the management of osteoarthritis.”

U.S. PREVENTIVE SERVICES TASK FORCE RECOMMENDATIONS
Not applicable.

ONGOING AND UNPUBLISHED CLINICAL TRIALS
Some currently unpublished trials that might influence this review are listed in Table 1.

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT02629380</td>
<td>Early Viscosupplementation After Partial Meniscectomy: a Double Blind, Placebo Controlled Randomized Trial</td>
<td>90</td>
<td>Mar 2016 (ongoing)</td>
</tr>
<tr>
<td>NCT02280538</td>
<td>Trial to Assess the Structural Effect and Long-term Symptomatic Relief of Intra-articular Injections of Hyaluronic Acid in Primary Knee OA (ViscOA)</td>
<td>300</td>
<td>Jan 2018</td>
</tr>
<tr>
<td>NCT02776514</td>
<td>Steroids, Hyaluronic Acid or Platelet Rich Plasma Versus Placebo for the Knee Osteoarthritis (KIT)</td>
<td>240</td>
<td>July 2018</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.
CODING

The following codes for treatment and procedures applicable to this policy are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

HCPCS

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J7320</td>
<td>Hyaluronan or derivative, Genvisc 850, for intra-articular injection, 1 mg</td>
</tr>
<tr>
<td>J7321</td>
<td>Hyaluronan or derivative, Hyalgan or Supartz, for intra-articular injection, per dose</td>
</tr>
<tr>
<td>J7322</td>
<td>Hyaluronan or derivative, Hyalmovis, for intra-articular injection, 1 mg</td>
</tr>
<tr>
<td>J7323</td>
<td>Hyaluronan or derivative, Euflexxa, for intra-articular injection, per dose</td>
</tr>
<tr>
<td>J7324</td>
<td>Hyaluronan or derivative, Orthovisc, for intra-articular injection, per dose</td>
</tr>
<tr>
<td>J7325</td>
<td>Hyaluronan or derivative, Synvisc or Synvisc-One, for intra-articular injection, 1 mg</td>
</tr>
<tr>
<td>J7326</td>
<td>Hyaluronan or derivative, Gel One, for intra-articular injection, per dose</td>
</tr>
<tr>
<td>J7327</td>
<td>Hyaluronan or derivative, Monovisc, for intra-articular injection, per dose</td>
</tr>
<tr>
<td>J7328</td>
<td>Hyaluronan or derivative, gel-syn, for intra-articular injection, 0.1 mg</td>
</tr>
</tbody>
</table>

REVISIONS

<table>
<thead>
<tr>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>01-01-2007</td>
<td>Added HCPCS Codes: Q4083, Q4084, Q4085, Q4086</td>
</tr>
<tr>
<td>03-31-2007</td>
<td>Deleted HCPCS Code: J 7319</td>
</tr>
<tr>
<td>12-31-2007</td>
<td>Deleted HCPCS Codes: Q4083, Q4084, Q4085, Q4086</td>
</tr>
<tr>
<td>01-01-2008</td>
<td>Added HCPCS Codes: J7321, J7322, J7323, J7324.</td>
</tr>
<tr>
<td>12-24-2008</td>
<td>In Description:</td>
</tr>
<tr>
<td></td>
<td>• Revised wording from &quot;...intra-articular lubricants in patients with any musculoskeletal condition, including osteoarthritis.&quot; To &quot;...intra-articular lubricants in patients with osteoarthritis of the knee.&quot;</td>
</tr>
<tr>
<td></td>
<td>• Added &quot;The use of hyaluronan injections may be considered medically necessary when all of the following are met:&quot; ahead of the three criteria.</td>
</tr>
<tr>
<td>01-01-2010</td>
<td>In Coding Section:</td>
</tr>
<tr>
<td></td>
<td>• Added HCPCS Code: J7325</td>
</tr>
<tr>
<td></td>
<td>• Removed HCPCS Code: J7322</td>
</tr>
<tr>
<td></td>
<td>In Policy Section / Utilization:</td>
</tr>
<tr>
<td></td>
<td>• Added: &quot;Synvisc-One is a single injection treatment regimen&quot;</td>
</tr>
<tr>
<td>01-01-2012</td>
<td>In the Coding section:</td>
</tr>
<tr>
<td></td>
<td>• Added HCPCS code: J7326</td>
</tr>
<tr>
<td>09-24-2012</td>
<td>In the Policy Title, removed &quot;of the Knee&quot; to read &quot;Intra-articular Hyaluronan Injections for Osteoarthritis&quot;</td>
</tr>
<tr>
<td></td>
<td>Description section updated.</td>
</tr>
<tr>
<td></td>
<td>Added Medical Policy and Coding Disclaimers.</td>
</tr>
<tr>
<td></td>
<td>In the Policy section:</td>
</tr>
<tr>
<td></td>
<td>• Revised the following policy language:</td>
</tr>
<tr>
<td></td>
<td>The use of hyaluronan injections may be considered medically necessary when all of the following are met:</td>
</tr>
<tr>
<td></td>
<td>1. Diagnosis of Osteoarthritis (degenerative arthritis) for knee only.</td>
</tr>
<tr>
<td></td>
<td>2. Failed conservative treatment, i.e., anti-inflammatory agents, physical therapy, weight loss, activity modification, knee brace, and occasional corticosteroid injection. Reconstructive surgery where a knee is unstable and surgery is indicated.</td>
</tr>
<tr>
<td></td>
<td>3. The series of injections (one course) can be repeated every six months.</td>
</tr>
</tbody>
</table>
In the Utilization portion, added:
- Euflexxa® is a 3-5 dose course of treatments.
- Gel One® is a 3-5 dose course of treatments.
- Orthovisc® is a 3-5 dose course of treatments.

Added Rationale section.

Updated Reference section.

10-26-2012
- In the Utilization section, removed the 4th bullet, "Gel One® is a 3-5 dose course of treatments."
- In the Utilization section, last sentence, added "® and Gel-One® are" and removed "is" to read "Synvisc-One® and Gel-One® are a single injection treatment regimen."

10-01-2013
- Updated Description section.

In Policy section:
- Revised the following medical policy language:
  "A. Intra-articular hyaluronan injections may be considered medically necessary for treatment of painful osteoarthritis of the knee in patients who have insufficient pain relief from conservative nonpharmacologic therapy and simple analgesics.
B. Repeated courses of intra-articular hyaluronan injections of the knee may be considered medically necessary under the following conditions:
  - Significant pain relief achieved with the prior course of injections; and
  - At least 6 months have passed since completion of the prior course.
C. The use of intra-articular hyaluronan injections in joints other than the knee is considered experimental / investigational."
- Removed "Utilization" section.
- Added "FDA Approved Indications and Dosage" table.

In Coding section:
- Added ICD-10 Diagnosis codes. (Effective October 1, 2014)

Updated Rationale section.

Updated Reference section.

05-01-2014
- Removed links to Prior Authorization information and Drug Formulary.

Updated Description section.

In Policy section:
- Changed the current medical policy language
From:
"A. Preferred Viscosupplements may be considered medically necessary when ALL the following are met:
1. The patient has a diagnosis of OA of the knee AND
2. The patient has tried and failed to respond adequately to conservative nonpharmacologic therapy AND to simple analgesics [acetaminophen or NSAIDs] AND
3. ONE of the following:
   a. The patient is receiving his/her first course of viscosupplement OR
   b. The patient's previous course of viscosupplement was at least 6 months previous OR
   c. The request is for the other knee joint not previously treated AND
4. The dose of the requested agent is within FDA labeled dosing guidelines.
B. Non-preferred Viscosupplements may be considered medically necessary when all of the following are met:
1. The patient has a diagnosis of OA of the knee AND
2. The patient has tried and failed to respond adequately to conservative nonpharmacologic therapy AND simple analgesics [acetaminophen or NSAIDs] AND
3. ONE of the following:
   a. The patient has evidence of use of the preferred agent in pharmacy claims or
medical history at least 6 months prior to request of the non-preferred agent OR
b. The patient has a documented intolerance, FDA labeled contraindication, or
hypersensitivity to the preferred viscosupplement agent. AND
4. It has been at least 6 months since the patient used the preferred agent OR any
other viscosupplement for the same knee joint AND
5. The dose of the requested agent is within FDA labeled dosing guidelines
C. Repeated courses of intra-articular hyaluronan injections of the knee may be
considered medically necessary under the following conditions:
1. Significant pain relief achieved with the prior course of injections; AND
2. At least 6 months have passed since completion of the prior course.
D. The use of intra-articular hyaluronan in the knee when the above criteria are not
met, and injections in joints other than the knee is considered experimental /
investigational."
To: "Intra-articular hyaluronan injections are considered not medically necessary."

Updated Rationale section.
In Coding section:
• Removed Diagnoses codes
Updated Reference section.
01-01-2016
In Coding section:
• Added HCPCS codes: J7328, Q9980.
Updated References section.
04-01-2016
In Coding section:
• Added HCPCS code: C9471.
07-22-2016
Updated Description section.
In Policy section:
• In Item A, added "of the knee" to read "Intra-articular hyaluronan injections of the
knee are considered not medically necessary."
• Added Item B, "Intra-articular hyaluronan injections are considered experimental /
investigational for all other joints.
Updated Rationale section.
Updated References section.
01-01-2017
In Coding section:
• Added HCPCS codes: J7320, J7322 (New codes, effective January 1, 2017).
05-24-2017
Updated Description section.
Updated Rationale section.
In Coding section:
• Added HCPCS code: J7327.
• Removed HCPCS codes: Q9980, C9471.
Updated References section.

REFERENCES
1. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Intra-Articular
Hyaluronan Injections for Treatment of Osteoarthritis of the Knee. TEC Assessments 1998;Volume
13:Tab 17.
2. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Special Report: intra-
knee (Evidence Reports/Technology Assessments No. 157). Rockville, MD: Agency for Healthcare
Research and Quality; 2007.
4. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Intra-articular hyaluronic


Other References
2. Blue Cross and Blue Shield of Kansas Medical Advisory Committee, April 2007.
3. Blue Cross and Blue Shield of Kansas Family Practice Liaison Committee, July 2014.